🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Eikonizo's Rebecca James had a steady stream of highly engaged visitors during her poster presentation on next-generation HDAC6 inhibitors for #ParkinsonsDisease at the Keystone Symposium for Neurodegenerative Diseases in Santa Fe last week.  More to come! #KSNeurodegen24

Eikonizo Therapeutics team are in Stockholm this week presenting important new research highlighting our highly selective CNS-penetrant HDAC6i for #ALS, and our novel HDAC6 PET tracer to measure in vivo target engagement. Lots of interest at our ENC ALS 2024 poster sessions. Onward!

Eikonizo Therapeutics is excited to be in Philly for the Alzheimer's Association #AAIC24. A great opportunity to learn from and meet with some of the best and brightest in dementia research. If you see our CEO Rick Lundberg, be sure to stop and say hello!

For the 10th anniversary of the #IceBucketChallenge, our CEO Rick Lundberg joyfully participated in the #CEOSoak. What a good sport! Who's next? #icebucket10

Eikonizo Therapeutics is taking it on the road this month to showcase the breadth of our data across #neurodegenerative diseases, including #ALS, #FTD and #Parkinsons. Stop by our posters at #SfN24 in Chicago on 10/9 and at #NEALSMtg in FL on 10/23 to learn more! Society for Neuroscience (SfN) NEALS Consortium

Eikonizo Therapeutics researcher Rebecca James (Rebecca James) is on site at #SfN24 in Chicago, ready to discuss our data in #Parkinsons disease. Stop by poster #D19 from 1-4pm CT today and say hi!

So rewarding to see NV-5138/SPN-820 advancing as a potential therapy for people suffering from Treatment-Resistant Depression (#TRD). Navitor Pharma's collab w Supernus Pharmaceuticals Inc. (inked virtually in early days of the #COVID19 shutdown) is bearing fruit! ir.supernus.com/news-releases/…

Exclusive: After 60 years, scientists finally know why ginger, calico, and tortoiseshell #cats look the way they do. bit.ly/4eTU84K News from Science

We’re thrilled to announce an investment by Novo Nordisk which will support development of our lead candidate EKZ-102 for ALS and enable the advancement of our novel HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease. businesswire.com/news/home/2024…

Today we also announced key additions to strengthen our leadership, including Tom Hughes, who joins our Board, as well as Rich Fisher as CSO, Jim Luterman as EVP, Development and Jon Graves as VP, Finance and Controller. Learn more about our team here: eikonizo.com/our-team/

Eikonizo Therapeutics team will be kicking off the new year with meetings in SF during the 43rd Annual J.P. Morgan Healthcare Conference #JPM2025 ! We are excited to discuss our progress and upcoming milestones. Learn more here: eikonizo.com #JPMorgan #HDACinhibitor

“Trump is just casually making major international crimes into policy proposals. He just normalizes violating, or proposing to violate, the absolute bedrock principles of international law.” nytimes.com/2025/02/05/wor…

Completely agree with dereklowe[at]bsky[dot]social This is not a time to keep our heads down and hope the storm passes... science.org/content/blog-p…

Work hard, play hard! Eikonizo Therapeutics prides itself on being a team-oriented and fun place to work, as these pics from our recent social gaming outing at #Level99 can attest. #TeamBuilding #WorkHardPlayHard

350 million people worldwide are affected by rare diseases—yet too often, they feel alone. Every 90 minutes, someone is diagnosed with ALS, and another life is lost to this relentless disease. But there is power in connection. By sharing your ALS story, you are helping influence

Congratulations to Merit Cudkowicz, MD, MSc, on receiving the American Action Network Lifetime Achievement Award for Clinically Relevant Research! Her dedication to collaboration, innovation, and open science is fast-tracking discoveries and transforming ALS care. #AANAM

Neural pathways that generate intelligent thought evolved at least two separate times in vertebrates. quantamagazine.org/intelligence-e…

Completely agree with Otello: "This is a business of selectivity..." (Despite the market, I'm feeling rather agreeable today.) statnews.com/2025/04/07/ome… via STAT

Agree! Great gathering of so many friends in industry, academic and patient advocacy groups working together to beat #ALS! als-drug-development.com

linkedin.com/posts/maia-jad…